Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation
NCT05886998Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of heparin in smoke inhalation injury (2 arms), sponsored by Ain Shams University. Primary endpoint: Ventilator-Free Days at 28 days. Started Jun 2023; status: completed.
02
Drugs
heparin
03
Conditions
smoke inhalation injury
Beyond the preview
Go deeper on NCT05886998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886998.